PotentiaMetrics

What PotentiaMetrics does

PotentiaMetrics is an Austin, Texas-based private company that provides personalized and predictive analytics for treatment decision-making in complex conditions, primarily cancer and end-stage renal disease (ESRD). The company's core asset is Capire360, a proprietary decision-support platform built on advanced statistical modeling and real-world outcomes data from over 2 million patients across more than 500 centers, refined over a decade and validated by Erasmus University Medical Center. Capire360 includes 15 cancer models covering approximately 85% of cancer cases and a separate ESRD module that helps nephrologists identify suitable home dialysis candidates; the platform's distinguishing claim is the ability to isolate outcomes by individual treatment modality, including combinations and no-treatment comparators, presented as "people like me" evidence.

On top of Capire360, PotentiaMetrics operates Ardynn, an independent cancer advocacy service that delivers Personalized Shared Decision-Making (PSDM) by pairing human advocates with the platform's real-world evidence. Ardynn (formerly branded MyCancerJourney until a 2025 rebrand) is offered as an employee/member benefit through health plans and self-insured employers, and is referenced to cancer patients by oncologists at the start of the diagnostic process.

The company monetizes through a mix of enterprise licensing (Capire360 to providers and health systems), subscription/benefit arrangements (Ardynn distributed through health plans and self-insured employers, with employer participation growing from 20 to over 500 between 2023 and 2024), and international SaaS distribution via a healthcare technology master distributor. Primary customer segments are health plans and payviders, self-insured employers, oncologists and nephrologists, and individual cancer patients. The company was founded in 2015 with grants from the National Cancer Institute, Barnes-Jewish Hospital Foundation, and the founder's family estate; it has remained privately held and founder-led under CEO Robert Palmer, with a small team of 1–10 employees.

Name

PotentiaMetrics

Legal name

PotentiaMetrics, Inc.

Website

https://potentiametrics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

PotentiaMetrics provides AI-driven personalized treatment decision support and cancer advocacy through its Capire360 analytics platform and Ardynn advocacy service. It serves health plans, self-insured employers, oncologists, nephrologists, and cancer patients facing complex conditions.

Ownership category

akta.pro rank

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Capire360 Software Licensing: Licensable software solution for healthcare providers and health systems. Capire360 for Cancer built for oncologists; Capire360 for ESRD built for nephrologists.
2. Ardynn Advocacy Services: Independent cancer advocacy service offered as a benefit by employers, health plans, and providers to their employees, members, and patients. Revenue flows through health plan and employer benefit arrangements.
3. International SaaS Distribution: MyCancerJourney sold as SaaS internationally through healthcare technology master distributor partnerships, particularly targeting countries with socialized medicine systems.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

PotentiaMetrics sells Capire360, a proprietary treatment decision support platform that turns real-world outcomes from over 2 million patient experiences into personalized survival and treatment predictions for oncologists and nephrologists. It also sells Ardynn, an independent cancer advocacy service that combines human advocates with Capire360 data to deliver Personalized Shared Decision-Making, distributed as a benefit through employers, health plans, and providers.

Product overview

PotentiaMetrics provides a unified healthcare analytics platform combining high-tech analytics powered by real-world data with high-touch patient support for personalized healthcare decisions. The core product portfolio consists of Ardynn (a cancer advocacy service delivering Personalized Shared Decision-Making through dedicated advocates) and Capire360 (a treatment decision support platform with specialized modules for cancer and end-stage renal disease). Ardynn leverages Capire360's real-world outcomes data to deliver personalized insights, while Capire360 serves oncologists, nephrologists, and advocates as a licensable software solution. The company previously operated MyCancerJourney (now rebranded to Ardynn) and originally developed PotentiaMED for cardiac surgery outcomes.

Differentiator

Problem solved

Functional benefit

Brands

• Ardynn: An independent cancer advocacy service that employers, health plans, and providers offer as a benefit to their employees, members, and patients. Provides personalized shared decision-making support combining compassionate human advocates with Capire360 real-world outcomes insights.
• Capire360

Products and services

• Ardynn An independent cancer advocacy service that combines compassionate human advocates with real-world outcomes insights from Capire360 to deliver Personalized Shared Decision-Making support for patients facing cancer diagnoses. Offered as a benefit by employers, health plans, and providers.
• Capire360 A proprietary treatment decision support platform powered by advanced statistical modeling that transforms clinical data from millions of patient experiences into personalized survival and treatment outcome insights. Used by oncologists, nephrologists, and Ardynn advocates.
• Capire360 for Cancer Licensable software solution for cancer treatment decision support, built for oncologists and health systems. Includes 15 cancer models covering 85% of cancer cases where adjuvant therapies are considered, with personalized outcomes matched by patient demographics, health status, comorbidities, and individual treatment modalities.
• Capire360 for ESRD Licensable software solution for end-stage renal disease (ESRD) treatment decision support, built for nephrologists. Identifies ideal candidates for home dialysis by matching patient labs, comorbidities, and disease causes against outcomes from similar patients.

Quantifiable outcome

• Nearly half of cancer treatments don't provide expected benefits, representing $100 billion annually in US healthcare spending
• +1 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• First National US Health PlancoreChannel Partner/ Reseller/ Distributor · 1 January 2022First national US health plan partnership offering MyCancerJourney/Ardynn advocacy solution as a benefit to self-insured employers. Marked beginning of PotentiaMetrics integration into health plan market. More employers recognized value of supporting employees with personalized cancer support.
• National Dialysis Care ProvidercoreStrategic or Co-development Partner · 1 January 2022Approached PotentiaMetrics to develop an outcomes tool specifically for individuals with End-Stage Renal Disease (ESRD). Company successfully created and tested Capire360 for ESRD, informing providers which patients are best candidates for home care.
• International Healthcare Technology Master DistributorcoreChannel Partner/ Reseller/ Distributor · 1 January 2021Partnership focused on advancing health equity by putting cancer models in the hands of oncologists globally. Many countries with socialized medicine need to ensure appropriate treatment options are available to patients. In this context, MyCancerJourney/Ardynn is sold as SaaS through this distribution partner.
• GuideWell/Florida Blue CrosscoreStrategic or Co-development Partner · 1 January 2016Selected to participate and was the top-rated company in the GuideWell/Florida Blue Cross Accelerator. This accelerator program provided mentorship, resources, and recognition for innovative healthcare companies. The partnership marked early national recognition for PotentiaMetrics.
• Erasmus University Medical CentercoreTechnology or Integration · 1 January 2015Experts from Erasmus University Medical Center, one of the world's top programs in medical decision-making and prognostic modeling, validated the models and methodology. Erasmus University confirmed the accuracy and reliability of the cancer models. The cancer models were validated and models continue to be compared to national databases to ensure accuracy.
• Covidien, Medtronic, SorinminorStrategic or Co-development Partner · 1 January 2005PotentiaMED (predecessor to PotentiaMetrics) partnered with Covidien, Medtronic, and Sorin. These partnerships established the company as a trusted third-party tool for analyzing and reporting outcomes for value-based care in cardiac surgery.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Flatiron Health: Oncology-focused real-world data and EHR platform (Roche subsidiary) that aggregates clinical and outcomes data to support cancer care and research. Directly comparable to PotentiaMetrics' Capire360 in building real-world oncology evidence and decision support.
• ConcertAI: Real-world evidence and AI company focused on oncology, partnering with providers, payers, and life sciences to inform cancer care. Comparable to PotentiaMetrics in building oncology real-world evidence datasets to support treatment decisions.
• Tempus: AI-powered precision medicine company with a major oncology focus that uses real-world patient data to support treatment decisions. Comparable to PotentiaMetrics' combination of real-world evidence, predictive modeling, and oncology clinical decision support.
• CancerIQ: Cancer risk assessment and clinical decision support platform used by providers to identify high-risk patients and personalize screening and treatment. Comparable to PotentiaMetrics' Capire360 in delivering cancer-focused decision support tools to clinicians.
• Navigating Cancer: Patient engagement platform for oncology practices that helps patients manage treatment, communicate with care teams, and access decision support. Comparable to PotentiaMetrics' Ardynn advocacy service in providing patient-facing cancer decision support.
• Syapse: Oncology real-world evidence platform partnering with health systems and life sciences companies to inform cancer treatment decisions. Comparable to PotentiaMetrics in applying real-world oncology data to clinical decision support.

Broad incumbents

• Health Catalyst: Healthcare analytics and data platform serving health systems and payers with outcomes measurement and improvement solutions. Comparable to PotentiaMetrics in applying analytics to real-world outcomes to support value-based care decisions.
• Elsevier ClinicalPath (formerly Via Oncology): Established oncology decision support platform providing evidence-based treatment pathways used by large health systems. Comparable to Capire360 as a clinician-facing oncology decision support tool, but part of Elsevier's broader clinical content portfolio.

Emerging players

• Outcomes4Me: Cancer patient app delivering personalized treatment information, clinical trial matching, and decision support. Comparable to Ardynn in giving patients actionable, personalized cancer insights, but focused on self-serve rather than advocate-led delivery.

Others

• Personify Health (formerly Virgin Pulse): Employee wellbeing and health benefit platform serving self-insured employers. Comparable to PotentiaMetrics in selling into the self-insured employer channel for health benefits, but adjacent rather than directly competitive.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/potentiametrics
• LinkedInlinkedin.com/company/potentia-metrics

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PotentiaMetrics